Skip to main content
NASDAQ:LEXX

Lexaria Bioscience Competitors

$6.19
-0.31 (-4.77 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.01
$6.50
50-Day Range
$4.61
$6.50
52-Week Range
$3.98
$9.46
Volume118,036 shs
Average Volume812,242 shs
Market Capitalization$31.59 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Lexaria Bioscience (NASDAQ:LEXX) Vs. BHP, RIO, VALE, FCX, SCCO, and CLF

Should you be buying LEXX stock or one of its competitors? Companies in the industry of "metal mining" are considered alternatives and competitors to Lexaria Bioscience, including BHP Group (BHP), Rio Tinto Group (RIO), Vale (VALE), Freeport-McMoRan (FCX), Southern Copper (SCCO), and Cleveland-Cliffs (CLF).

BHP Group (NYSE:BHP) and Lexaria Bioscience (NASDAQ:LEXX) are both basic materials companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for BHP Group and Lexaria Bioscience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BHP Group18702.38
Lexaria Bioscience0000N/A

Profitability

This table compares BHP Group and Lexaria Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BHP GroupN/AN/AN/A
Lexaria Bioscience-1,046.77%-157.62%-148.09%

Institutional and Insider Ownership

0.1% of Lexaria Bioscience shares are owned by institutional investors. 0.0% of BHP Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BHP Group and Lexaria Bioscience's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BHP Group$42.93 billion2.90$7.96 billion$3.5821.64
Lexaria Bioscience$380,000.0083.14$-4,090,000.00N/AN/A

BHP Group has higher revenue and earnings than Lexaria Bioscience.

Summary

BHP Group beats Lexaria Bioscience on 7 of the 9 factors compared between the two stocks.

Lexaria Bioscience (NASDAQ:LEXX) and Rio Tinto Group (NYSE:RIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lexaria Bioscience and Rio Tinto Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
Rio Tinto Group19802.39

Profitability

This table compares Lexaria Bioscience and Rio Tinto Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
Rio Tinto GroupN/AN/AN/A

Institutional & Insider Ownership

0.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 7.5% of Rio Tinto Group shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Lexaria Bioscience and Rio Tinto Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.0083.14$-4,090,000.00N/AN/A
Rio Tinto Group$43.17 billion2.55$8.01 billion$6.3313.94

Rio Tinto Group has higher revenue and earnings than Lexaria Bioscience.

Summary

Rio Tinto Group beats Lexaria Bioscience on 7 of the 8 factors compared between the two stocks.

Lexaria Bioscience (NASDAQ:LEXX) and Vale (NYSE:VALE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lexaria Bioscience and Vale, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
Vale21802.55

Vale has a consensus target price of $18.20, indicating a potential downside of 13.46%. Given Vale's higher probable upside, analysts clearly believe Vale is more favorable than Lexaria Bioscience.

Profitability

This table compares Lexaria Bioscience and Vale's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
Vale7.33%25.65%10.46%

Institutional & Insider Ownership

0.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 19.0% of Vale shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Lexaria Bioscience and Vale's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.0083.14$-4,090,000.00N/AN/A
Vale$37.57 billion2.87$-1,683,000,000.00$1.6013.14

Lexaria Bioscience has higher earnings, but lower revenue than Vale.

Summary

Vale beats Lexaria Bioscience on 7 of the 9 factors compared between the two stocks.

Lexaria Bioscience (NASDAQ:LEXX) and Freeport-McMoRan (NYSE:FCX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lexaria Bioscience and Freeport-McMoRan, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
Freeport-McMoRan051112.76

Freeport-McMoRan has a consensus target price of $27.00, indicating a potential downside of 36.16%. Given Freeport-McMoRan's higher probable upside, analysts clearly believe Freeport-McMoRan is more favorable than Lexaria Bioscience.

Profitability

This table compares Lexaria Bioscience and Freeport-McMoRan's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
Freeport-McMoRan-0.73%1.56%0.67%

Institutional & Insider Ownership

0.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 72.3% of Freeport-McMoRan shares are owned by institutional investors. 1.0% of Freeport-McMoRan shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Lexaria Bioscience and Freeport-McMoRan's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.0083.14$-4,090,000.00N/AN/A
Freeport-McMoRan$14.40 billion4.28$-239,000,000.00$0.022,114.50

Lexaria Bioscience has higher earnings, but lower revenue than Freeport-McMoRan.

Summary

Freeport-McMoRan beats Lexaria Bioscience on 9 of the 11 factors compared between the two stocks.

Lexaria Bioscience (NASDAQ:LEXX) and Southern Copper (NYSE:SCCO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lexaria Bioscience and Southern Copper, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
Southern Copper52001.29

Southern Copper has a consensus target price of $49.9286, indicating a potential downside of 34.56%. Given Southern Copper's higher probable upside, analysts clearly believe Southern Copper is more favorable than Lexaria Bioscience.

Profitability

This table compares Lexaria Bioscience and Southern Copper's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
Southern Copper17.17%18.67%7.95%

Institutional & Insider Ownership

0.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 6.9% of Southern Copper shares are owned by institutional investors. 0.5% of Southern Copper shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Lexaria Bioscience and Southern Copper's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.0083.14$-4,090,000.00N/AN/A
Southern Copper$7.29 billion8.10$1.49 billion$1.9239.74

Southern Copper has higher revenue and earnings than Lexaria Bioscience.

Summary

Southern Copper beats Lexaria Bioscience on 8 of the 9 factors compared between the two stocks.

Lexaria Bioscience (NASDAQ:LEXX) and Cleveland-Cliffs (NYSE:CLF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lexaria Bioscience and Cleveland-Cliffs, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexaria Bioscience0000N/A
Cleveland-Cliffs03302.50

Cleveland-Cliffs has a consensus target price of $21.44, indicating a potential upside of 9.89%. Given Cleveland-Cliffs' higher probable upside, analysts clearly believe Cleveland-Cliffs is more favorable than Lexaria Bioscience.

Profitability

This table compares Lexaria Bioscience and Cleveland-Cliffs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexaria Bioscience-1,046.77%-157.62%-148.09%
Cleveland-Cliffs-3.38%-2.69%-0.35%

Institutional & Insider Ownership

0.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 67.6% of Cleveland-Cliffs shares are owned by institutional investors. 1.8% of Cleveland-Cliffs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Lexaria Bioscience and Cleveland-Cliffs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexaria Bioscience$380,000.0083.14$-4,090,000.00N/AN/A
Cleveland-Cliffs$1.99 billion4.90$292.80 million$1.1217.42

Cleveland-Cliffs has higher revenue and earnings than Lexaria Bioscience.

Summary

Cleveland-Cliffs beats Lexaria Bioscience on 9 of the 10 factors compared between the two stocks.


Lexaria Bioscience Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BHP Group logo
BHP
BHP Group
1.4$77.47-0.3%$124.42 billion$42.93 billion21.64News Coverage
Rio Tinto Group logo
RIO
Rio Tinto Group
1.7$88.23-2.0%$110.11 billion$43.17 billion13.94Unusual Options Activity
Vale logo
VALE
Vale
2.0$21.03-1.1%$107.85 billion$37.57 billion41.24News Coverage
Freeport-McMoRan logo
FCX
Freeport-McMoRan
1.9$42.29-0.8%$61.68 billion$14.40 billion-469.84Analyst Upgrade
Gap Down
Southern Copper logo
SCCO
Southern Copper
1.1$76.30-1.1%$58.99 billion$7.29 billion45.69
Cleveland-Cliffs logo
CLF
Cleveland-Cliffs
1.5$19.51-1.5%$9.74 billion$1.99 billion-69.68
MP Materials logo
MP
MP Materials
1.7$26.14-5.9%$4.46 billionN/A0.00Gap Down
Turquoise Hill Resources logo
TRQ
Turquoise Hill Resources
1.6$16.53-1.9%$3.33 billion$1.17 billion8.52Earnings Announcement
Analyst Downgrade
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Compañía de Minas Buenaventura S.A.A. logo
BVN
Compañía de Minas Buenaventura S.A.A.
0.8$11.72-5.2%$2.98 billion$867.89 million-22.98Gap Down
Hudbay Minerals logo
HBM
Hudbay Minerals
1.8$8.08-1.1%$2.11 billion$1.24 billion-13.69Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Pretium Resources logo
PVG
Pretium Resources
2.0$11.19-3.4%$2.10 billion$484.54 million22.84Analyst Report
Gap Down
Lithium Americas logo
LAC
Lithium Americas
1.1$12.70-4.9%$1.52 billion$4.84 million-34.32Gap Down
Nexa Resources logo
NEXA
Nexa Resources
1.4$11.05-2.3%$1.46 billion$2.33 billion-2.39Analyst Upgrade
EMX Royalty logo
EMX
EMX Royalty
0.0$3.44-4.1%$281.23 million$3.83 million-68.80
Westwater Resources logo
WWR
Westwater Resources
1.0$3.84-4.4%$124.17 millionN/A-1.34News Coverage
U.S. Gold logo
USAU
U.S. Gold
1.4$10.66-1.0%$75.25 millionN/A-3.36News Coverage
Opiant Pharmaceuticals logo
OPNT
Opiant Pharmaceuticals
0.5$12.15-2.1%$52.62 million$40.52 million-121.48Earnings Announcement
News Coverage
Gap Up
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.